Sophia Genetics Sa ( (SOPH) ) has released its Q4 earnings. Here is a breakdown of the information Sophia Genetics Sa presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SOPHiA GENETICS SA is a cloud-native healthcare technology company specializing in data-driven medicine, utilizing AI to provide insights for cancer and rare disorder treatments globally. The company recently released its financial results for the fourth quarter and full year of 2024, highlighting a modest revenue increase and improvements in operating losses. Key financial metrics showed a 4% year-over-year revenue growth, reaching $65.2 million, and an adjusted gross margin increase to 72.8%. The company also reported a significant operating loss reduction by 20% on an adjusted basis. SOPHiA GENETICS achieved notable business milestones, including a record number of analyses and customer acquisitions, and expanded its platform with new applications like the Liquid Biopsy MSK-ACCESS®. Looking ahead, the company is optimistic about accelerating growth in 2025, driven by new product launches and strategic partnerships, particularly in the U.S. market.